

doximity

NOTE TO REVIEWER: Boxed content is variable and may change if multiple titles and images are presented. Unboxed content will not change.

Sponsored


Variable Title Options:

This is a Test Title purely for **Testing Purposes.** [80 characters and spaces; limit: 120] How Is this another Title? Of course it is, and again is only for testing.

[105 characters and spaces; limit: 120] See Are you still reading... go home - there's nothing to see here. This is only a test.

[119 characters and spaces; limit: 120]

Merck
[X] colleagues read This is a Test Title purely for Testing Purposes. Prescribing Info Med Guide



Options. See How They Compare.

Adult Formulation: NDC 0006-4096-02 - Carton of ten 50U/1-mL prefilled single-dose Luer-Lok® syringes with tip caps

Indication

VAQTA® (Hepatitis A Vaccine, Inactivated) is indicated for the prevention of disease caused by hepatitis A virus (HAV) in persons 12 months of age and older. The primary dose should be given at least 2 weeks prior to expected exposure to HAV.

Dosage and Administration

- Adults (19 years of age and older): The vaccination schedule consists of a primary 1 mL dose administered intramuscularly and a 1 mL booster dose administered intramuscularly 6 to 18 months later.
- Booster Immunization Following Another Manufacturer's Hepatitis A Vaccine: A booster dose of VAQTA may be given at 6 to 12 months following a primary dose of *Havrix**.

*Havrix is a registered trademark of GlaxoSmithKline.

Select Safety Information

- Do not administer VAQTA to individuals with a history of immediate and/or severe allergic or hypersensitivity reactions (eg, anaphylaxis) after a previous dose of any hepatitis A vaccine, or to individuals who have had an anaphylactic reaction to any component of VAQTA, including neomycin.
- The vial stopper and the syringe plunger stopper and tip cap contain dry natural latex rubber that may cause allergic reactions in latex-sensitive individuals.

Select Safety Information continues below

Learn More About VAQTA

Download Printable Dosing Resource Select Safety Information (continued)

- The most common local adverse reactions and systemic adverse events (≥15%) reported in different clinical trials across different age groups when VAQTA was administered alone or concomitantly were: Adults 19 years of age and older: injection
 - site pain, tenderness, or soreness (67.0%), injection site warmth (18.2%), and headache (16.1%).
- individuals receiving immunosuppressive therapy, may have a diminished immune response to VAQTA and may not be protected against HAV infection after vaccination.

• Immunocompromised persons, including

protective response in all susceptible vaccinees.

Vaccination with VAQTA may not result in a

• VAQTA may be administered concomitantly with Immune Globulin, human, using separate sites and syringes.

• There are no adequate and well-controlled

studies designed to evaluate VAQTA in pregnant women, including those 19 years of age or younger. Available post-approval data do not suggest an increased risk of miscarriage or major birth defects in women who received VAQTA during pregnancy.

• It is not known whether VAQTA is excreted

- in human milk. Data are not available to assess the effects of VAQTA on the breastfed infant or on milk production/excretion. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for VAQTA and any potential adverse effects on the breastfed child from VAQTA or from the underlying maternal condition.
- VAQTA in healthy vaccinees is unknown at present.

• In clinical trials in adults, VAQTA was

• The total duration of the protective effect of

concomitantly administered with typhoid Vi polysaccharide and yellow fever vaccines. Safety and immunogenicity were similar for concomitantly administered vaccines compared to separately administered vaccines.

Before administering VAQTA, please read the accompanying Prescribing Information. The Patient

All trademarks referenced are properties of their respective owners.


Copyright © 2022 Merck & Co., Inc., Kenilworth,

Information also is available.

US-VAQ-00785 01/22

NJ, USA and its affiliates. All rights reserved.

Dialer



Desktop View

doximity

Variable Title Options:


This is a Test Title purely for Testing Purposes.
[80 characters and spaces; limit: 120]

How Is this another Title? Of course it is, and again is only for testing.


[105 characters and spaces; limit: 120]

See Are you still reading... go home – there's nothing to see here. This is only a test.

[119 characters and spaces; limit: 120]



NOTE TO REVIEWER: Boxed content is variable and may change if multiple titles and images are presented. Unboxed content will not change.



Adult Formulation: NDC 0006-4096-02 - Carton of ten 50U/1-mL prefilled single-dose Luer-Lok $^{\circledR}$ syringes with tip caps

Indication

VAQTA[®] (Hepatitis A Vaccine, Inactivated) is indicated for the prevention of disease caused by hepatitis A virus (HAV) in persons 12 months of age and older. The primary dose should be given at least 2 weeks prior to expected exposure to HAV.

Dosage and Administration

- Adults (19 years of age and older): The vaccination schedule consists of a primary 1 mL dose administered intramuscularly and a 1 mL booster dose administered intramuscularly 6 to 18 months later.
- Booster Immunization Following Another Manufacturer's Hepatitis A Vaccine: A booster dose of VAQTA may be given at 6 to 12 months following a primary dose of Havrix*.

*Havrix is a registered trademark of GlaxoSmithKline.

Select Safety Information

- Do not administer VAQTA to individuals with a history of immediate and/or severe allergic or hypersensitivity reactions (eg, anaphylaxis) after a previous dose of any hepatitis A vaccine, or to individuals who have had an anaphylactic reaction to any component of VAQTA, including neomycin.
- The vial stopper and the syringe plunger stopper and tip cap contain dry natural latex rubber that may cause allergic reactions in latex-sensitive individuals.

Select Safety Information continues below

Learn More About VAQTA

Download Printable Dosing Resource

Select Safety Information (continued)

- The most common local adverse reactions and systemic adverse events (≥15%) reported in different clinical trials across different age groups when VAQTA was administered alone or concomitantly were:
- Adults 19 years of age and older: injection-site pain, tenderness, or soreness (67.0%), injection site warmth (18.2%), and headache (16.1%).
- Immunocompromised persons, including individuals receiving immunosuppressive therapy, may have a diminished immune response to VAQTA and may not be protected against HAV infection after vaccination.
- Vaccination with VAQTA may not result in a protective response in all susceptible vaccinees.
- VAQTA may be administered concomitantly with Immune Globulin, human, using separate sites and syringes.
- There are no adequate and well-controlled studies designed to evaluate VAQTA in pregnant women, including those 19 years of age or younger. Available post-approval data do not suggest an increased risk of miscarriage or major birth defects in women who received VAQTA during pregnancy.
- It is not known whether VAQTA is excreted in human milk. Data are not available to assess the effects of VAQTA on the breastfed infant or on milk production/excretion. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for VAQTA and any potential adverse effects on the breastfed child from VAQTA or from the underlying maternal condition.
- The total duration of the protective effect of VAQTA in healthy vaccinees is unknown at present.
- In clinical trials in adults, VAQTA was concomitantly administered with typhoid Vi polysaccharide and yellow fever vaccines. Safety and immunogenicity were similar for concomitantly administered vaccines compared to separately administered vaccines.

Before administering VAQTA, please read the accompanying Prescribing Information.

The Patient Information also is available.

All trademarks referenced are properties of their respective owners.

Copyright © 2022 Merck & Co., Inc., Kenilworth, NJ, USA and its affiliates. All rights reserved.

US-VAQ-00785 01/22

